This activity is supported by educational grants from Bristol Myers Squibb; Genentech, a member of the Roche Group; Merck Sharp & Dohme Corp.; and Regeneron Pharmaceuticals, Inc and Sanofi.
Oncology NPs, PAs, and nurses
Upon completion of this activity, participants should be able to:
Identify currently approved ICIs and the role of biomarker testing in their use in advanced NSCLC
Describe recommended, evidence-based strategies to individualize treatment with ICIs for patients with advanced NSCLC
Implement effective strategies for identification and management of immune-related adverse events in patients treated with ICIs
All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Elizabeth Krueger, NP, has no relevant financial relationships to disclose.
None of the members of the Planning Committee or PCE staff have any relevant financial relationships to disclose.
Participants wishing to earn CE/CME credit must:
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 67%.
The estimated time to complete this activity is 1.50 hours.
Release date: August 17, 2022
Expiration date: August 16, 2023
In this virtual simulation platform program, you will meet 3 patients with non-small-cell lung cancer. The program will have you proceed through your patient’s history, overview of the current situation, and physical exam. It enables you to obtain additional information by ordering laboratory values, imaging, and to make referrals. As the patient scenario warrants, add your recommendations for diagnosis, treatments, and follow-up. End your patient visit and schedule a follow-up. At each end-of-visit, you will see your progress in achieving the predetermined goals for the case. Each case will test your ability to diagnose and prescribe evidence-based recommendations to improve care.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.
Joint Accreditation Statement
In support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ANCC Credit Designation
Nursing contact hours: 1.50, which includes 1.50 hours of pharmacology credit
AAPA Credit Designation
Practicing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.50 AAPA Category 1 CME credits. Approval is valid until August 16, 2023. PAs should only claim credit commensurate with the extent of their participation.
PA course advisor: Jessica Garner, DMSc, PA-C, University of the Pacific, Sacramento, California
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 1.50 Interprofessional Continuing Education (IPCE) credits for learning and change.
This program has been made available online.